欧美日韩精品无码专区,成年无码av片,成品漫画免登录去广告版,亚洲精品一区国产

美國Alexion Pharmaceuticals
Alexion制藥公司是一家生物制藥企業(yè)，致力于為罹患重癥致命疾病的患者開發(fā)生產(chǎn)救命藥物。Alexion公司從事治療藥物的探索、開發(fā)和推廣，這些藥物用于治療種類廣泛的嚴重疾病，包括血液系統(tǒng)和腎臟疾病、移植、癌癥和自身免疫疾病。Soliris是Alexion公司首個上市的藥物。Alexion公司正在評估Soliris治療其他適應證的可能性、以及依庫珠單抗其他劑型治療附加臨床適應證的可能性，其他處于早期開發(fā)階段的抗體備選產(chǎn)品也正在開發(fā)中。

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris? (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.